Switch theme
Sign up to access all valuation multiples
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
2003
286
LTM Revenue $86.7M
LTM EBITDA -$126M
$549M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zymeworks has a last 12-month revenue (LTM) of $86.7M and a last 12-month EBITDA of -$126M.
In the most recent fiscal year, Zymeworks achieved revenue of $76.3M and an EBITDA of -$109M.
Zymeworks expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zymeworks valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $86.7M | XXX | $76.3M | XXX | XXX | XXX |
| Gross Profit | $86.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$126M | XXX | -$109M | XXX | XXX | XXX |
| EBITDA Margin | -145% | XXX | -142% | XXX | XXX | XXX |
| EBIT | -$131M | XXX | -$120M | XXX | XXX | XXX |
| EBIT Margin | -151% | XXX | -157% | XXX | XXX | XXX |
| Net Profit | -$119M | XXX | -$123M | XXX | XXX | XXX |
| Net Margin | -137% | XXX | -161% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Zymeworks's stock price is $11.
Zymeworks has current market cap of $796M, and EV of $549M.
See Zymeworks trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $549M | $796M | XXX | XXX | XXX | XXX | $-1.61 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Zymeworks has market cap of $796M and EV of $549M.
Zymeworks's trades at 7.2x EV/Revenue multiple, and -5.1x EV/EBITDA.
Equity research analysts estimate Zymeworks's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zymeworks has a P/E ratio of -6.7x.
See valuation multiples for Zymeworks and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $796M | XXX | $796M | XXX | XXX | XXX |
| EV (current) | $549M | XXX | $549M | XXX | XXX | XXX |
| EV/Revenue | 6.3x | XXX | 7.2x | XXX | XXX | XXX |
| EV/EBITDA | -4.4x | XXX | -5.1x | XXX | XXX | XXX |
| EV/EBIT | -4.2x | XXX | -4.6x | XXX | XXX | XXX |
| EV/Gross Profit | 6.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.7x | XXX | -6.5x | XXX | XXX | XXX |
| EV/FCF | -6.6x | XXX | -4.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZymeworks's last 12 month revenue growth is 42%
Zymeworks's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.7M for the same period.
Zymeworks's rule of 40 is -117% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zymeworks's rule of X is -41% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Zymeworks and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | 42% | XXX | XXX | XXX |
| EBITDA Margin | -145% | XXX | -142% | XXX | XXX | XXX |
| EBITDA Growth | -11% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -117% | XXX | -101% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -41% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 176% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 257% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zymeworks acquired XXX companies to date.
Last acquisition by Zymeworks was XXXXXXXX, XXXXX XXXXX XXXXXX . Zymeworks acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Zymeworks founded? | Zymeworks was founded in 2003. |
| Where is Zymeworks headquartered? | Zymeworks is headquartered in United States of America. |
| How many employees does Zymeworks have? | As of today, Zymeworks has 286 employees. |
| Who is the CEO of Zymeworks? | Zymeworks's CEO is Mr. Kenneth Galbraith. |
| Is Zymeworks publicy listed? | Yes, Zymeworks is a public company listed on NAS. |
| What is the stock symbol of Zymeworks? | Zymeworks trades under ZYME ticker. |
| When did Zymeworks go public? | Zymeworks went public in 2017. |
| Who are competitors of Zymeworks? | Similar companies to Zymeworks include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Zymeworks? | Zymeworks's current market cap is $796M |
| What is the current revenue of Zymeworks? | Zymeworks's last 12 months revenue is $86.7M. |
| What is the current revenue growth of Zymeworks? | Zymeworks revenue growth (NTM/LTM) is 42%. |
| What is the current EV/Revenue multiple of Zymeworks? | Current revenue multiple of Zymeworks is 6.3x. |
| Is Zymeworks profitable? | Yes, Zymeworks is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zymeworks? | Zymeworks's last 12 months EBITDA is -$126M. |
| What is Zymeworks's EBITDA margin? | Zymeworks's last 12 months EBITDA margin is -145%. |
| What is the current EV/EBITDA multiple of Zymeworks? | Current EBITDA multiple of Zymeworks is -4.4x. |
| What is the current FCF of Zymeworks? | Zymeworks's last 12 months FCF is -$83.7M. |
| What is Zymeworks's FCF margin? | Zymeworks's last 12 months FCF margin is -97%. |
| What is the current EV/FCF multiple of Zymeworks? | Current FCF multiple of Zymeworks is -6.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
